Mustafa Broachwala

Mustafa Broachwala

Auto-generated profile, based on publicly available information

Mustafa Broachwala

Department of Anesthesiology and Pain University of California San Diego San Diego California USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2024 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
DJDavid S Jevotovsky
David S Jevotovsky
HCHarman Chopra
Harman Chopra
DPDaniel J Pak
Daniel J Pak
SDShravani Durbhakula
Shravani Durbhakula
ASAlexander Shustorovich
Alexander Shustorovich
JCJoel P Castellanos
Joel P Castellanos
Background/Importance Chronic pain affects many people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain management despite being classified as Schedule I. Objective This systematic review critically evaluates the evidence for psilocybin, a Schedule I substance, in the treatment of chronic pain. The exact purpose of the review is to assess the impact of psilocybin on chronic pain relief, focusing on dosing protocols, treated conditions, and patient outcomes. Evidence Review A comprehensive review of PubMed, CINAHL, Web of Science, Cochrane Library, and EMBASE was conducted up to January 2024. Eligibility criteria included studies evaluating psilocybin for chronic pain management. The risk of bias was assessed using the MASTER (MethodologicAl STandards for Epidemiological Research) scale, and the strength of evidence was graded using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation). Findings The review identified 28 relevant studies focusing on dosing, treated conditions, and outcomes. The majority of the included studies (76.2%) were of low or very low quality. Several studies with moderate-to-low-quality evidence utilized a 0.14 mg/kg dosing protocol. The findings suggest promise for the use of psilocybin in chronic pain relief, though the quality of evidence is generally low. Conclusions The current research shows potential for psilocybin as a treatment option for chronic pain relief. However, methodological issues and a lack of high-quality evidence underscore the need for further investigations with standardized protocols. Despite these limitations, the potential for psilocybin in chronic pain management is encouraging. PROSPERO registration number CRD42023493823.

20 April 2024 in World Neurosurgery
Verified
Journal Article
Closed access
KRKathleen Ran
Kathleen Ran
ODOishika Das
Oishika Das
DJDavid T. Johnston
David T. Johnston
NVNeha Vutakuri
Neha Vutakuri
SRSruthi Ranganathan
Sruthi Ranganathan
DLDaniel Lubelski
Daniel Lubelski

29 April 2025 in Clinical Case Reports
Verified
Journal Article
Open access
MBMustafa Broachwala
Mustafa Broachwala
DBDylan W. Banks
Dylan W. Banks
DJDavid S. Jevotovsky
David S. Jevotovsky
WOWhitman Oehlermarx
Whitman Oehlermarx
SDShravani Durbhakula
Shravani Durbhakula
This is the first reported case of burning mouth syndrome resulting from the Pfizer‐BioNTech COVID‐19 vaccine. It highlights the efficacy of a unique multimodal treatment regimen, including zinc supplementation, acupuncture, and topical capsaicin.

28 March 2025 in Pain Medicine
Verified
Journal Article
Open access
NSNathaniel M Schuster
Nathaniel M Schuster
MBMustafa Broachwala
Mustafa Broachwala
FAFarshad M Ahadian
Farshad M Ahadian
CACharles E Argoff
Charles E Argoff
SCSteven P Cohen
Steven P Cohen
ABAntje M Barreveld
Antje M Barreveld

12 March 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
DJDavid S Jevotovsky
David S Jevotovsky
HCHarman Chopra
Harman Chopra
DPDaniel J Pak
Daniel J Pak
EGEric A Grin
Eric A Grin
APAdhith Palla
Adhith Palla
VOVwaire Orhurhu
Vwaire Orhurhu
Background/Importance Chronic coccydynia is a challenging condition to manage. Conflicting evidence exists regarding the role of the ganglion impar in coccygeal nociception. When conservative treatments fail, minimally invasive interventions at the ganglion impar may be effective in providing relief. Objectives To evaluate the effectiveness and safety of ganglion impar blocks (GIBs) for the management of chronic coccydynia. Evidence review A systematic review and meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies were identified through a comprehensive literature search of PubMed, Embase Classic+ Embase, CINAHL and the Web of Science in February 2024. Data on patient characteristics, intervention details, pain outcomes (measured by Visual Analog Scale and Numerical Pain Rating Scale) and adverse events were extracted. Meta-analysis was performed using standardized mean differences (SMDs) on scale of 0 to 10. Findings Seventeen studies described 625 coccydynia patients treated with GIB. All studies reported some level of improvement of pain after GIB. The meta-analysis included 11 studies totaling 391 patients with a baseline pain score of 7.93 (7.81 to 8.04 95% CI). GIBs were effective in reducing coccygeal pain at short-term (up to 3 months), intermediate-term (3–6 months) and long-term (greater than 6 months) follow-up. SMDs were −2.73 (95% CI −3.45 to −2.01), −3.22 (95% CI −2.82 to −1.45), −1.86 (95% CI −2.58 to −1.15) at 3 months, 3–6 months and >6 months, respectively. No serious adverse events were noted. Grading of Recommendations Assessment, Development and Evaluation assessment indicated ‘very low’ certainty of evidence across all outcomes. Conclusions Non-neurodestructive GIB may be a safe and potentially effective treatment option for patients with chronic, refractory coccydynia. PROSPERO registration number CRD42024506056.

2 February 2025 in Clinical Case Reports
Verified
Journal Article
Open access
MSMichael Suarez
Michael Suarez
DGDavid M. Gallacher
David M. Gallacher
DJDavid S. Jevotovsky
David S. Jevotovsky
HCHarman Chopra
Harman Chopra
MBMustafa Broachwala
Mustafa Broachwala
JCJoel P. Castellanos
Joel P. Castellanos
Spinal cord stimulation (SCS) is a promising therapy for the management of spinal cord injury. Following SCS, this patient experienced a significant reduction in pain and decreased spasticity, which ultimately led to improved upper extremity function.